Back

Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure therapies: timing, choices, and comparative effectiveness Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Hilson Amorim Parente

National Institute of Cardiology - Rua das Laranjeiras, Rio de Janeiro (Brazil)

4 More presentations in this session

Presentation thumbnail
From trials to treatment: real-world vericiguat initiation and residual risk in Germany
Doctor F. Kerwagen (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety
Doctor N. Benameur (Tangier, MA)
Abstract Slides Video
Presentation thumbnail
Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials
Doctor E. Alupei (RO)
Abstract Slides Video
Presentation thumbnail
Early catheter ablation for atrial fibrillation in acute heart failure: prognostic impact across age and ejection fraction
Doctor A. Okahara (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure therapies: timing, choices, and comparative effectiveness

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Levosimendan in heart transplantation: a systemic review and meta-analysis
29 August 2026
thumbnail
Congress Presentation
Diuretic therapy strategies in decompensated acute heart failure: a systematic review and network metanalysis
2 September 2024
thumbnail
Congress Presentation
Changes in hemodynamic, strain and myocardial work parameters predict long term mortaility and rehospitalization in acute, decompensated heart failure after levosimendan administration.
13 May 2024
thumbnail
Congress Presentation
Levosimendan in patients with cardiogenic shock refractory to dobutamine weaning
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources